Rohtak News Magazine

200+ Leading Prostate Cancer Pipeline Companies are working to improve the Treatment Landscape

 Breaking News
  • No posts were found

200+ Leading Prostate Cancer Pipeline Companies are working to improve the Treatment Landscape

February 27
10:16 2023

DelveInsight’s, “Prostate Cancer Pipeline Insight, 2023,” report provides comprehensive insights about 200+ companies and 200+ pipeline drugs in the Prostate Cancer pipeline landscape. It covers the Prostate Cancer pipeline drug profiles, including Prostate Cancer clinical trials and nonclinical stage products. It also covers the Prostate Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

For Prostate Cancer emerging drugs, the Prostate Cancer pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Prostate Cancer pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

 

In the Prostate Cancer Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Prostate Cancer clinical trials studies, Prostate Cancer NDA approvals (if any), and product development activities comprising the technology, Prostate Cancer collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

Key takeaways from the Prostate Cancer Pipeline Report

 

  • Over 200+ Prostate Cancer companies are evaluating 200+ Prostate Cancer pipeline therapies in various stages of development, and their anticipated acceptance in the Prostate Cancer market would significantly increase market revenue.

 

  • The leading Prostate Cancer Companies includes Pfizer, Myovant Biosciences, Effector Therapeutics, Mediolanum, Merck, ESSA Pharma, Sanofi, Astellas Pharma, AstraZeneca, Bayer, Janssen research & development LLC, Bristol Myers Squibb, Eli Lilly and Company, Amgen, POINT Biopharma, Hinnova Pharmaceuticals, Sophiris Bio, Ultimovacs, Foresee Pharmaceuticals, Luye Pharma Group, Abbott, AB science, Ferring pharmaceuticals, Jiangsu HengRui Medicine, Hoffmann-La Roche, Novartis, Celgene, Endocyte, Millennium Pharmaceuticals, Medivation, Veru, Progenics Pharmaceuticals, Boehringer Ingelheim, US Biotest, Antev, Elevation oncology, Abgenix, Astellas Pharma, Orion Pharma, Clovis Oncology, Exelixis, Takeda, Novus Therapeutics, Candel Therapeutics, Ipsen, MEI Pharma, Aragon Pharmaceuticals, MedImmune,  CytRx, Tmunity Therapeutics, Inovio Pharmaceuticals, Forma Therapeutics, Luye Pharma, Health Ever Bio-Tech, Advaxis, Corcept Therapeutics and several others.

 

  • Promising Prostate Cancer Pipeline Therapies such as P PSMA 101, Autologous adipose-derived mesenchymal stem cell therapy, EPI 7386, ODM 208, MCS 8, ADXS PSA, Exicorilant, VERU-100, and others

 

  • The Prostate Cancer companies and academics are working to assess challenges and seek opportunities that could influence Prostate Cancer R&D. The Prostate Cancer pipeline therapies under development are focused on novel approaches to treat/improve Prostate Cancer.

  

To explore more information on the latest breakthroughs in the Prostate Cancer Pipeline treatment landscape of the report, click here @ Prostate Cancer Pipeline Outlook

 

Prostate Cancer Overview

The prostate is a small walnut shaped gland in the pelvis of men. It is located next to the bladder and can be examined by getting a digital rectal exam. Prostate Cancer is a form of cancer that develops in the prostate gland. It is the second-leading cause of cancer deaths for men in the U.S. About 1 in 9 men will be diagnosed with Prostate Cancer in their lifetime. This year, nearly 250,000 men will be diagnosed with Prostate Cancer. Prostate Cancer cells can spread by breaking away from a prostate tumor. They can travel through blood vessels or lymph nodes to reach other parts of the body. After spreading, cancer cells may attach to other tissues and grow to form new tumors, causing damage where they land.

 

Latest Developmental Activities in the Prostate Cancer Treatment Landscape

 

  • In February 2023, Fusion Pharmaceuticals announced the acquisition from RadioMedix, Inc. of the investigational new drug application for an ongoing Phase II clinical trial (the “TATCIST” trial) evaluating 225Ac-PSMA I&T, a small molecule targeting prostate-specific membrane antigen (“PSMA”) expressed on prostate cancers. Following the closing, the alpha-emitting radiopharmaceutical being evaluated in the TATCIST trial will be known as FPI-2265.

 

  • In February 2023, Corbus Pharmaceuticals entered into an exclusive licensing agreement with CSPC Megalith Biopharmaceutical Co., Ltd, a subsidiary of CSPC Pharmaceutical Group Limited for development and commercialization of CRB-701 (SYS6002): a novel clinical-stage antibody drug conjugate (ADC) targeting Nectin-4. The agreement covers exclusive commercialization rights to CRB-701 in the United States, Canada, the European Union (including the European Free Trade Area), the United Kingdom, and Australia. CSPC will retain all rights to SYS6002 in the remaining global markets. Clinical development is underway and will focus on urothelial cancer and other Nectin-4-positive solid tumors, potentially including lung, breast and prostate cancer.

 

  • In February 2023, BioXcel Therapeutics, Inc.reported full data from its Phase IIa trial of BXCL701, the Company’s investigational, oral innate immune activator, in combination with KEYTRUDA (pembrolizumab) in small cell neuroendocrine (SCNC) variant metastatic castration-resistant prostate cancer (mCRPC) patients after at least one prior line of chemotherapy for locally advanced or metastatic prostate cancer. Results will be presented in a rapid abstract presentation and a poster presentation at the 2023 American Society of Clinical Oncology Genitourinary Cancers (ASCO GU) Symposium on February 16, 2023.

 

  • In January 2023, Onxeo S.A. gave an update on the clinical development program of its first-in-class drug candidate AsiDNA. Onxeo has activated its first US clinical study site, Next Oncology San Antonio. This phase I/II multicenter, basket trial intends to assess the safety and preliminary activity of AsiDNA in combination with olaparib in patients with recurrent ovarian, breast, and metastatic castration-resistant prostate cancer (mCRPC) who have progressed on previous PARP inhibitor therapy.

 

  • In October 2022, Ayala Pharmaceuticals, Inc. and Advaxis, Inc. entered into a definitive merger agreement. The merger would result in a combined company that will focus predominantly on the development and commercialization of Ayala’s lead program AL102 for the treatment of desmoid tumors and Advaxis’s candidate ADXS-504 in development for prostate cancer.

 

  • In October 2022, Janux Therapeutics announced that the first patient had been dosed in Phase I clinical trial of JANX007 in subjects with metastatic castration-resistant prostate cancer (mCRPC). JANX007 is a prostate-specific membrane antigen (PSMA) directed T cell engager (TCE) and is the first product candidate utilizing Janux’s TRACTr platform to be administered in humans.

 

Request a sample and discover the recent advances in Prostate Cancer Ongoing Clinical Trial Analysis and Medications, click here @ Prostate Cancer Treatment Landscape

 

Prostate Cancer Emerging Drugs Profile

 

Pembrolizumab: Merck & Co

Keytruda (pembrolizumab) is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2. Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors. Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. Currently, it is in phase 3 stage of development to treat Prostate Cancer.

 

Talazoparib: Pfizer

Talazoparib is an inhibitor of PARP enzymes, which play a role in DNA repair. Preclinical studies suggest that talazoparib may work by blocking PARP enzyme activity and trapping PARP at the site of DNA damage, leading to decreased cancer cell growth and cancer cell death. Talazoparib anti-tumor activity also was observed in mouse models of human breast cancer that expressed mutated or non-mutated BRCA1/2.

 

ODM-208: Orion

ODM 208, an orally bioavailable, non-steroid selective inhibitor of CYP11A1 (cholesterol side-chain cleavage enzyme), is being developed by Orion. Steroid hormones stimulate the growth of hormonally regulated cancers, such as most prostate and breast cancers. Hormonal treatments are highly effective, but drug resistance will often eventually emerge and cancer will start growing again. The molecule (ODM-208) has shown antitumor activity. It has potential efficacy also for those cancers that have become resistant to the standard hormonal treatments. Currently, it is in phase 2 stage of development to treat Prostate Cancer.

 

ZEN 3694: Zenith Epigenetics

The company’s lead product, ZEN-3694, a BET inhibitor, in combination with enzalutamide, is in a Phase 2 randomized clinical trial for treatment of metastatic castration resistant Prostate Cancer (mCRPC) in patients that have progressed on an androgen receptor signaling inhibitor.

 

EPI-7386: ESSA Pharma

EPI-7386 is an investigational, highly-selective, oral, small molecule inhibitor of the N-terminal domain of the androgen receptor. EPI-7386 is currently being studied in a Phase 1 clinical trial (NCT04421222) in men with metastatic castration-resistant Prostate Cancer (“”mCRPC””) whose tumors have progressed on current standard-of-care therapies. The Phase I clinical trial of EPI-7386 began in Q3 of 2020 following FDA allowance of the IND and Health Canada acceptance. The U.S. FDA has granted Fast Track designation to EPI-7386 for the treatment of adult male patients with mCRPC resistant to standard-of-care treatment. ESSA retains all rights to EPI-7386 worldwide.

 

Prostate Cancer Pipeline Therapeutics Assessment

There are approx. 200+ key companies which are developing the therapies for Prostate Cancer. The companies which have their Prostate Cancer drug candidates in the most advanced stage, i.e. phase III include, Merck & Co.

 

For further information, refer to the detailed Prostate Cancer Unmet Needs, Prostate Cancer Market Drivers, and Market Barriers, click here for Prostate Cancer Ongoing Clinical Trial Analysis

 

Scope of the Prostate Cancer Pipeline Report

 

  • Coverage- Global

 

  • Prostate Cancer Companies- Pfizer, Myovant Biosciences, Effector Therapeutics, Mediolanum, Merck, ESSA Pharma, Sanofi, Astellas Pharma, AstraZeneca, Bayer, Janssen research & development LLC, Bristol Myers Squibb, Eli Lilly and Company, Amgen, POINT Biopharma, Hinnova Pharmaceuticals, Sophiris Bio, Ultimovacs, Foresee Pharmaceuticals, Luye Pharma Group, Abbott, AB science, Ferring pharmaceuticals, Jiangsu HengRui Medicine, Hoffmann-La Roche, Novartis, Celgene, Endocyte, Millennium Pharmaceuticals, Medivation, Veru, Progenics Pharmaceuticals, Boehringer Ingelheim, US Biotest, Antev, Elevation oncology, Abgenix, Astellas Pharma, Orion Pharma, Clovis Oncology, Exelixis, Takeda, Novus Therapeutics, Candel Therapeutics, Ipsen, MEI Pharma, Aragon Pharmaceuticals, MedImmune,  CytRx, Tmunity Therapeutics, Inovio Pharmaceuticals, Forma Therapeutics, Luye Pharma, Health Ever Bio-Tech, Advaxis, Corcept Therapeutics, and others.

 

  • Prostate Cancer Pipeline Therapies- P PSMA 101, Autologous adipose-derived mesenchymal stem cell therapy, EPI 7386, ODM 208, MCS 8, ADXS PSA, Exicorilant, VERU-100, and others.

 

  • Prostate Cancer Pipeline Segmentation: Phases, Product Type, Mechanism of action, Route of administration, Molecule Type

 

Dive deep into rich insights for drugs for Prostate Cancer Market Drivers and Prostate Cancer Market Barriers, click here @ Prostate Cancer Unmet Needs and Analyst Views

 

Table of Content

  1. Introduction
  2. Prostate Cancer Executive Summary
  3. Prostate Cancer: Overview
  4. Prostate Cancer Pipeline Therapeutics
  5. Prostate Cancer Therapeutic Assessment
  6. Late Stage Products (Phase III)
  7. Pembrolizumab: Merck & Co
  8. Drug profiles in the detailed report….
  9. Mid Stage Products (Phase II)
  10. ODM-208: Orion Pharma
  11. Drug profiles in the detailed report….
  12. Early Stage Products (Phase I)
  13. EPI 7386: ESSA Pharma
  14. Drug profiles in the detailed report….
  15. Preclinical and Discovery Products
  16. Drug name: Company name
  17. Drug profiles in the detailed report…
  18. Inactive Products
  19. Prostate Cancer Key Companies
  20. Prostate Cancer Key Products
  21. Prostate Cancer- Unmet Needs
  22. Prostate Cancer- Market Drivers and Barriers
  23. Prostate Cancer- Future Perspectives and Conclusion
  24. Prostate Cancer Analyst Views
  25. Prostate Cancer Key Companies
  26. Appendix

 

Got Queries? Find out the related information on Prostate Cancer Mergers and acquisitions, Prostate Cancer Licensing Activities @ Prostate Cancer Emerging Drugs, and Recent Trends

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services